Clinical Studies
Salvia BioElectronics initiated the first studies to evaluate the safety and performance of the MySalvia Migraine Therapy for the treatment of migraine and cluster headache.
We are committed to conducting ethical and high-quality clinical trials. Please note that while we establish the inclusion and exclusion criteria for our studies, we do not directly select the patients who participate. Patient selection is the responsibility of our collaborating physicians. These medical professionals carefully evaluate potential participants based on the criteria we provide to ensure that the trial is conducted safely and effectively. We trust their expertise and judgment in this process and value their cooperation in advancing medical research.
Salvia’s device is not yet approved for commercial use. We make no claims about safety or effectiveness.
.jpg)
Migraine Study (RECLAIM) in Belgium, The Netherlands, United Kingdom and Australia
A double-blind, sham-controlled study to evaluate effectiveness and safety in patients with resistant migraine. Recruitment is ongoing.
Migraine Study (RELIEF) in Belgium
The first evaluation of Salvia’s bioelectronic foil for people with chronic migraine is ongoing (“RELIEF”). Recruitment for this study is complete.
Cluster Headache Study (RESPONSE) in Australia
The first evaluation of Salvia’s bioelectronic foil for people with chronic cluster headache has started (“RESPONSE”). Recruitment for this study is complete.
Salvia Insights
Later in 2024, we will provide updates on our latest clinical trials and other developments. Stay informed about Salvia's mission?
We value your privacy and will only use your email to send you updates about Salvia BioElectronics. Your information will always remain confidential and will not be shared with third parties. You can unsubscribe at any time.